UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 29

Sortiert nach

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.14-32

2013

Link zum Volltext

Verfügbarkeit prüfen

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors

Chest, 2013-04, Vol.143 (4), p.955-962

2013

Link zum Volltext

Verfügbarkeit prüfen

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

Chest, 2013-04, Vol.143 (4), p.955-962

2013

Link zum Volltext

Verfügbarkeit prüfen

A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer

BMC medicine, 2014-06, Vol.12 (1), p.93-93, Article 93

2014

Link zum Volltext

Verfügbarkeit prüfen

Everolimus Plus Octreotide Long‐Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT‐2 Study

The oncologist (Dayton, Ohio), 2013-01, Vol.18 (1), p.46-53

2013

Link zum Volltext

Verfügbarkeit prüfen

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI : Journal of the National Cancer Institute, 2023-09, Vol.115 (9), p.1001-1010

2023

Link zum Volltext

Verfügbarkeit prüfen

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

Current medical research and opinion, 2014-06, Vol.30 (6), p.1007-1016

2014

Link zum Volltext

Verfügbarkeit prüfen

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe

BMC cancer, 2015-10, Vol.15 (1), p.787-787, Article 787

2015

Link zum Volltext

Verfügbarkeit prüfen

Everolimus Plus Octreotide Lar in Patients with Lung Carcinoids

Journal of thoracic oncology, 2014, Vol.9 (9), p.S179

2014

Link zum Volltext

Verfügbarkeit prüfen

Everolimus plus exemestane in patients with advanced invasive lobular carcinoma: Efficacy and safety results from BOLERO-2

Journal of clinical oncology, 2014-09, Vol.32 (26_suppl), p.152-152

2014

Link zum Volltext

Verfügbarkeit prüfen

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive (HR + ), HER2-negative (HER2 – ) advanced breast cancer (ABC) in Europe

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e17520-e17520

2013

Link zum Volltext

Verfügbarkeit prüfen

Post-Progression Therapies in Patients with Advanced Neuroendocrine Tumors (NET): Analysis From the RADIANT-2 Trial: 216

The American journal of gastroenterology, 2011-10, Vol.106, p.S85-S86

2011

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Everolimus Plus Octreotide LAR in Patients With Colorectal Neuroendocrine Tumors (NET): Subgroup Analysis of the Phase III RADIANT-2 Trial: 394

The American journal of gastroenterology, 2011-10, Vol.106, p.S154-S155

2011

Link zum Volltext

Verfügbarkeit prüfen

BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER + , HER2 - metastatic breast cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS661-TPS661

2013

Link zum Volltext

Verfügbarkeit prüfen

Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4014-4014

2012

Link zum Volltext

Verfügbarkeit prüfen

Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4138-4138

2013

Link zum Volltext

Verfügbarkeit prüfen

Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)

Journal of clinical oncology, 2012-02, Vol.30 (4_suppl), p.157-157

2012

Link zum Volltext

Verfügbarkeit prüfen

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)

Leukemia, 1990-03, Vol.4 (3), p.177-183

1990

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe

2012

Link zum Volltext

Verfügbarkeit prüfen

Restoration of Responsiveness of Chronic Myeloid Leukemia Granulocyte-Macrophage Colony-Forming Cells to Growth Regulation In Vitro Following Preincubation With Prostaglandin E

Blood, 1983-07, Vol.62 (1), p.158-165

1983

Link zum Volltext

Verfügbarkeit prüfen

Intravenous gammaglobulin therapy in the management of a patient with idiopathic thrombocytopenic purpura and a warm autoimmune erythrocyte panagglutinin during pregnancy

Obstetrics and gynecology (New York. 1953), 1986-05, Vol.67 (5), p.741-746

1986

Link zum Volltext

Verfügbarkeit prüfen

Whole bone marrow irradiation for the treatment of multiple myeloma

Cancer, 1982-04, Vol.49 (7), p.1328-1333

1982

Link zum Volltext

Verfügbarkeit prüfen

MANAGEMENT OF FACTOR XI DEFICIENCY IN GYNECOLOGIC AND OBSTETRIC PATIENTS

Obstetrics and gynecology (New York. 1953), 1986-07, Vol.68 (1), p.130-133

1986

Link zum Volltext

Verfügbarkeit prüfen

Soft tissue T cell lymphoma of the forearm: A case report

The Journal of hand surgery (American ed.), 1984-05, Vol.9 (3), p.346-350

1984

Link zum Volltext

Verfügbarkeit prüfen

Localized Renal Aspergillosis with Hairy Cell Leukemia: A Review of Urinary Tract Aspergillosis in Malignant and Nonmalignant Conditions

Cancer investigation, 1984, Vol.2 (3), p.199-202

1984

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 29

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(28)
Webseiten
(1)

Sprache

Englisch
(29)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(15)
Science & Technology
(14)
Life Sciences & Biomedicine
(13)
Female
(12)
Oncology
(9)
Middle Aged
(8)
Adult
(7)
Biological And Medical Sciences
(7)
Male
(7)
Medical Sciences
(7)
Cancer
(4)
Chemotherapy
(4)
Everolimus
(4)
Sirolimus - Analogs & Derivatives
(4)
Advanced Breast Cancer
(3)
Aged
(3)
Antineoplastic Agents - Administration & Dosage
(3)
Disease-Free Survival
(3)
General & Internal Medicine
(3)
Gynecology. Andrology. Obstetrics
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors

Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study

A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer

Everolimus Plus Octreotide Long‐Acting Repeatable in Patients With Colorectal Neuroendocrine Tumors: A Subgroup Analysis of the Phase III RADIANT‐2 Study

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe

Everolimus Plus Octreotide Lar in Patients with Lung Carcinoids

Everolimus plus exemestane in patients with advanced invasive lobular carcinoma: Efficacy and safety results from BOLERO-2

Patterns of resource utilization and cost for postmenopausal women with hormone-receptor–positive (HR + ), HER2-negative (HER2 – ) advanced breast cancer (ABC) in Europe

Post-Progression Therapies in Patients with Advanced Neuroendocrine Tumors (NET): Analysis From the RADIANT-2 Trial: 216

Efficacy and Safety of Everolimus Plus Octreotide LAR in Patients With Colorectal Neuroendocrine Tumors (NET): Subgroup Analysis of the Phase III RADIANT-2 Trial: 394

BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER + , HER2 - metastatic breast cancer

Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)

Open-label, phase IIIb, multicenter, expanded access study of everolimus in patients with advanced neuroendocrine tumors (NET)

Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus (E+O) or placebo (P+O) among patients with advanced neuroendocrine tumors (NET)

Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL)

Patterns of Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe

Restoration of Responsiveness of Chronic Myeloid Leukemia Granulocyte-Macrophage Colony-Forming Cells to Growth Regulation In Vitro Following Preincubation With Prostaglandin E

Intravenous gammaglobulin therapy in the management of a patient with idiopathic thrombocytopenic purpura and a warm autoimmune erythrocyte panagglutinin during pregnancy

Whole bone marrow irradiation for the treatment of multiple myeloma

MANAGEMENT OF FACTOR XI DEFICIENCY IN GYNECOLOGIC AND OBSTETRIC PATIENTS

Soft tissue T cell lymphoma of the forearm: A case report

Localized Renal Aspergillosis with Hairy Cell Leukemia: A Review of Urinary Tract Aspergillosis in Malignant and Nonmalignant Conditions

Suchergebnisse filtern